STMP Group | Half-dose PDT Group | P value | |
---|---|---|---|
Variables | (n = 18) | (n = 21) | |
Age, mean ± SD, (years) | 37.22 ± 7.83 | 38.76 ± 8.08 | 0.582 |
Gender, (n) | |||
Male | 13 | 14 | |
Female | 5 | 7 | 0.742 |
Duration of symptoms, | |||
mean ± SD, (days) | 25.06 ± 16.09 | 21.33 ± 15.63 | 0.359 |
Baseline BCVA, mean ± SD, | |||
(ETDRS) | 63.67 ± 9.79 | 62.81 ± 8.52 | 0.772 |
Baseline CFT, mean ± SD, | |||
(μm) | 427.28 ± 52.23 | 423.38 ± 47.39 | 0.808 |
Baseline retinal | |||
sensitivity, mean ± SD, (dB) | 12.29 ± 1.88 | 12.61 ± 1.95 | 0.601 |
Presence of macular PED, (n) | 3(16.7%) | 5(23.8%) | 0.702 |
Location of leakage site, (n) | |||
Subfoveal | 2 | 4 | |
Juxtafoveal | 14 | 15 | |
Extrafoveal | 2 | 2 | 0.789 |
Number of leakage point, (n) | |||
1 | 15 | 16 | |
2 | 3 | 4 | |
3 | 0 | 1 | 0.622 |